{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053645","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.449285+00:00","generated_at":"2026-06-09T22:44:13.621857+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nkarta gets FDA IND clearance for NKX019 in LN; cuts workforce 10%, extends cash runway","bullets":["FDA cleared IND for NKX019 (CAR NK) for lupus nephritis; enrollment starts H1 2024; up to 12 patients.","RIF of 18 employees (~10% workforce); $1M-$1.5M severance costs in Q4 2023; extends cash runway into 2026.","Preliminary cash $278.4M as of Sep 30, 2023; cash runway extended one year into 2026.","NKX019 NHL: new compressed dosing cohort (Days 0,3,7) for LBCL; prior expansion cohorts discontinued.","Clinical updates in 2024: NKX101 AML H1, NKX019 NHL mid-2024, NKX019 LN in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053645","json":"https://secwatch.observer/filing/0000950170-23-053645.json","markdown":"https://secwatch.observer/filing/0000950170-23-053645.md","text":"https://secwatch.observer/filing/0000950170-23-053645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/nktx-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:44:13.621857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a71f76a72428154e7f4507651f4d27e85907fc80","claim":"Nkarta, Inc. announced a restructuring with charges of approximately $1 million to $1.5 million affecting Reduction in force of 18 positions, representing approximately 10% of the Company's workforce (reduction of 18 positions).","evidence_excerpt":"to extend the Company’s cash runway by one year into 2026. In connection with the implementation of the Reduction, the Company currently estimates it will incur approximately $1 million to $1.5 million in costs, consisting primarily of cash severance costs and transition support services for impacted employees, which the Company expects to recognize in the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023053645/0000950170-23-053645-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1 million to $1.5 million"},{"label":"Affected area","value":"Reduction in force of 18 positions, representing approximately 10% of the Company's workforce"},{"label":"Headcount","value":"reduction of 18 positions"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}